drospirenone has been researched along with Venous Thromboembolism in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (2.70) | 29.6817 |
| 2010's | 34 (91.89) | 24.3611 |
| 2020's | 2 (5.41) | 2.80 |
| Authors | Studies |
|---|---|
| Achilles, SL; Apolikhina, I; Archer, DF; Bouchard, C; Chen, MJ; Creinin, M; Foidart, JM; Jensen, JT; Jost, M; Kaunitz, AM; Piltonen, T; Suturina, L; Weyers, S; Zatik, J | 1 |
| Bester, J; de Lange-Loots, Z; Swanepoel, AC | 1 |
| Cagnacci, A | 1 |
| Cameron, S | 1 |
| Coulombe, J; Filion, KB; Larivée, N; Suissa, S; Tagalakis, V | 1 |
| Lidegaard, Ø | 1 |
| Conard, J; Gompel, A; Horellou, MH; Hugon-Rodin, J; Plu-Bureau, G | 1 |
| Hugon-Rodin, J; Plu-Bureau, G; Sabbagh, E | 1 |
| Abenhaim, HA; Eisenberg, MJ; Filion, KB; Grandi, SM; Joseph, L; Wu, CQ | 1 |
| Bird, ST; Brophy, JM; Delaney, JA; Etminan, M; Hartzema, AG | 1 |
| Casey, PM; Files, JA; Mayer, AP | 1 |
| Bardenheuer, K; Dinger, J; Heinemann, K | 1 |
| Reid, RL | 2 |
| Han, L; Jensen, JT | 1 |
| Beasley, R; Braithwaite, I; Shirtcliffe, P; Weatherall, M | 1 |
| Abenhaim, HA; Eberg, M; Eisenberg, MJ; Filion, KB; Joseph, L; Larivée, N; Suissa, S | 1 |
| Batur, P; Casey, PM | 1 |
| Filion, KB; Khosrow-Khavar, F; Larivée, N; Suissa, S; Tagalakis, V | 1 |
| Dinger, J | 1 |
| Culig, J; Eric, M; Leppée, M | 1 |
| Sehovic, N; Smith, KP | 1 |
| Assmann, A; Dinger, J; Minh, TD; Möhner, S | 1 |
| Reid, R | 1 |
| Hernandez, RK; Jick, SS; Parkin, L; Sharples, K | 1 |
| Hernandez, RK; Jick, SS | 1 |
| Dunn, N | 1 |
| Brown, DA; Vartan, CM | 1 |
| Heinemann, K; Heinemann, LA | 1 |
| Ribowsky, JH | 1 |
| Lidegaard, Ø; Løkkegaard, E; Nielsen, LH; Skjeldestad, FE; Skovlund, CW | 1 |
| Voelker, R | 1 |
| Dodd, S | 1 |
| Dinger, J; Shapiro, S | 1 |
| Sidney, S | 1 |
| Mansour, D; Shapiro, S; Szarewski, A | 1 |
6 review(s) available for drospirenone and Venous Thromboembolism
| Article | Year |
|---|---|
Hormonal contraception: venous and arterial disease.
Topics: Adult; Androstenes; Atherosclerosis; Contraceptives, Oral, Synthetic; Female; Humans; Levonorgestrel; Middle Aged; Risk Factors; Venous Thromboembolism | 2017 |
Drospirenone-containing oral contraceptive pills and the risk of venous and arterial thrombosis: a systematic review.
Topics: Androstenes; Arteries; Contraceptives, Oral, Hormonal; Female; Humans; Myocardial Infarction; Pulmonary Embolism; Risk; Stroke; Thrombosis; Venous Thromboembolism; Venous Thrombosis | 2013 |
Does the Progestogen Used in Combined Hormonal Contraception Affect Venous Thrombosis Risk?
Topics: Adult; Androstenes; Comorbidity; Contraceptives, Oral, Hormonal; Female; Humans; Intrauterine Devices, Medicated; Medical History Taking; Patient Selection; Progestins; Risk Assessment; Risk Factors; United States; Venous Thromboembolism | 2015 |
Drospirenone Litigation: Does the Punishment Fit the Crime?
Topics: Androstenes; Attitude of Health Personnel; Contraceptives, Oral, Combined; Female; Humans; Legislation, Drug; Mineralocorticoid Receptor Antagonists; Risk Factors; Venous Thromboembolism | 2017 |
Drospirenone-containing oral contraceptive pills and the risk of venous thromboembolism: a systematic review of observational studies.
Topics: Adult; Androstenes; Contraceptives, Oral, Combined; Female; Humans; Observational Studies as Topic; Risk Factors; Venous Thromboembolism | 2017 |
Risk of venous thromboembolism with drospirenone in combined oral contraceptive products.
Topics: Androstenes; Contraceptives, Oral, Combined; Female; Humans; Incidence; Progesterone Congeners; Risk; Venous Thromboembolism | 2010 |
2 trial(s) available for drospirenone and Venous Thromboembolism
| Article | Year |
|---|---|
Tolerability and safety of the estetrol/drospirenone combined oral contraceptive: Pooled analysis of two multicenter, open-label phase 3 trials.
Topics: Androstenes; Contraceptives, Oral, Combined; Estetrol; Estrogens; Ethinyl Estradiol; Female; Humans; Pregnancy; Venous Thromboembolism | 2022 |
Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives.
Topics: Adult; Androstenes; Contraceptives, Oral, Combined; Female; Humans; Mineralocorticoid Receptor Antagonists; Prospective Studies; Venous Thromboembolism; Young Adult | 2014 |
29 other study(ies) available for drospirenone and Venous Thromboembolism
| Article | Year |
|---|---|
Mechanical and Physical Behavior of Fibrin Clot Formation and Lysis in Combined Oral Contraceptive Users.
Topics: Adolescent; Adult; Androstenes; Blood Coagulation; Blood Coagulation Tests; Contraceptives, Oral, Combined; Ethinyl Estradiol; Female; Fibrin; Humans; Male; Microscopy, Electron, Scanning; Thrombelastography; Thrombosis; Venous Thromboembolism; Viscosity; Young Adult | 2020 |
Venous thromboembolism and combined hormonal contraception: what are the implications for prescribing?
Topics: Androstenes; Contraception; Contraceptives, Oral, Combined; Contraceptives, Oral, Hormonal; Female; Humans; Risk Factors; Venous Thromboembolism | 2017 |
Drospirenone-Containing Oral Contraceptive Pills and the Risk of Venous Thromboembolism: An Assessment of Risk in First-Time Users and Restarters.
Topics: Adolescent; Adult; Androstenes; Cohort Studies; Contraceptives, Oral, Combined; Drug Administration Schedule; Female; Humans; Levonorgestrel; Middle Aged; Proportional Hazards Models; Risk Factors; Venous Thromboembolism; Young Adult | 2017 |
Severely biased review of studies assessing the risk of venous thrombosis in users of drospirenone-containing oral contraceptives.
Topics: Androstenes; Contraceptives, Oral, Combined; Female; Humans; Venous Thromboembolism; Venous Thrombosis | 2018 |
Type of Combined Contraceptives, Factor V Leiden Mutation and Risk of Venous Thromboembolism.
Topics: Adolescent; Adult; Androstenes; Blood Coagulation Disorders, Inherited; Contraceptives, Oral, Combined; Contraceptives, Oral, Hormonal; Cyproterone Acetate; Factor V; Female; Humans; Incidence; Middle Aged; Paris; Premenopause; Progestins; Risk Factors; Venous Thromboembolism; Young Adult | 2018 |
[Hormonal contraception and vascular risk: CNGOF Contraception Guidelines].
Topics: Androstenes; Contraceptive Agents, Female; Contraceptives, Oral, Combined; Contraceptives, Oral, Hormonal; Cyproterone Acetate; Desogestrel; Female; France; Humans; Levonorgestrel; Norpregnenes; Progestins; Risk Factors; Vascular Diseases; Venous Thromboembolism | 2018 |
Drospirenone and non-fatal venous thromboembolism: is there a risk difference by dosage of ethinyl-estradiol?
Topics: Adolescent; Adult; Androstenes; Cohort Studies; Contraceptives, Oral; Databases, Factual; Ethinyl Estradiol; Female; Humans; Levonorgestrel; Middle Aged; Proportional Hazards Models; Risk; Time Factors; United States; Venous Thromboembolism; Young Adult | 2013 |
Drospirenone-related venous thromboembolism risk: "the rest of the story".
Topics: Adult; Androstenes; Contraceptives, Oral, Combined; Female; Humans; Risk Factors; Venous Thromboembolism; Young Adult | 2013 |
Oral hormonal contraception and venous thromboembolism (VTE).
Topics: Androstenes; Contraceptives, Oral, Combined; Female; Humans; Mineralocorticoid Receptor Antagonists; Venous Thromboembolism | 2014 |
Anti-androgen contraceptive pills and higher risk of venous thromboembolism.
Topics: Adolescent; Adult; Aged; Androgen Antagonists; Androstenes; Case-Control Studies; Contraceptives, Oral, Combined; Cyproterone Acetate; Female; Humans; Middle Aged; New Zealand; Risk Factors; Venous Thromboembolism; Young Adult | 2016 |
Drospirenone-containing combined oral contraceptives and the risk of arterial thrombosis: a population-based nested case-control study.
Topics: Adolescent; Adult; Androstenes; Case-Control Studies; Contraceptives, Oral, Combined; Drug Administration Schedule; Female; Humans; Levonorgestrel; Middle Aged; Risk Factors; United Kingdom; Venous Thromboembolism; Young Adult | 2017 |
Oral contraceptives and venous thromboembolism: old questions revisited.
Topics: Androstenes; Cohort Studies; Confounding Factors, Epidemiologic; Contraceptives, Oral; Humans; Progesterone Congeners; Venous Thromboembolism | 2009 |
Drospirenone and VTE.
Topics: Androstenes; Contraceptives, Oral, Combined; Croatia; Female; Hospitalization; Humans; Mineralocorticoid Receptor Antagonists; Venous Thromboembolism | 2010 |
Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study.
Topics: Adolescent; Adult; Androstenes; Case-Control Studies; Contraceptives, Oral; Estrogens; Ethinyl Estradiol; Female; Germany; Humans; Levonorgestrel; Logistic Models; Middle Aged; Mineralocorticoid Receptor Antagonists; Nandrolone; Risk Factors; Venous Thromboembolism; Young Adult | 2010 |
SOGC clinical practice guideline. No. 252, December 2010. Oral contraceptives and the risk of venous thromboembolism: an update.
Topics: Androstenes; Canada; Contraceptives, Oral; Contraceptives, Oral, Hormonal; Ethinyl Estradiol; Female; Humans; Risk Factors; Venous Thromboembolism | 2010 |
Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database.
Topics: Adolescent; Adult; Age Distribution; Androstenes; Case-Control Studies; Contraceptives, Oral; Contraceptives, Oral, Combined; Estrogens; Female; Humans; Levonorgestrel; Risk Factors; United Kingdom; Venous Thromboembolism; Young Adult | 2011 |
Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data.
Topics: Adolescent; Adult; Age Distribution; Androstenes; Case-Control Studies; Contraceptives, Oral, Combined; Female; Humans; Levonorgestrel; Risk Factors; United States; Venous Thromboembolism; Young Adult | 2011 |
The risk of deep venous thrombosis with oral contraceptives containing drospirenone.
Topics: Androstenes; Contraceptives, Oral, Combined; Female; Humans; Mineralocorticoid Receptor Antagonists; Venous Thromboembolism | 2011 |
Risk of venous thromboembolism with drospirenone-containing oral contraceptives.
Topics: Androstenes; Contraceptives, Oral, Combined; Humans; Patient Education as Topic; Research Design; Risk; Venous Thromboembolism | 2011 |
Comparative risks of venous thromboembolism among users of oral contraceptives containing drospirenone and levonorgestrel.
Topics: Androstenes; Contraceptives, Oral; Contraceptives, Oral, Synthetic; Female; Humans; Levonorgestrel; Mineralocorticoid Receptor Antagonists; Risk Assessment; Venous Thromboembolism | 2011 |
Do drospirenone-containing oral contraceptives have a higher risk of VTE?
Topics: Adult; Androstenes; Contraceptives, Oral; Ethinyl Estradiol; Female; Humans; Mineralocorticoid Receptor Antagonists; Venous Thromboembolism | 2011 |
Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9.
Topics: Adolescent; Adult; Androstenes; Anticoagulants; Cohort Studies; Confounding Factors, Epidemiologic; Contraceptives, Oral; Denmark; Desogestrel; Dose-Response Relationship, Drug; Epidemiologic Methods; Female; Humans; Intrauterine Devices, Medicated; Levonorgestrel; Middle Aged; Mineralocorticoid Receptor Antagonists; Norpregnenes; Pregnancy; Time Factors; Venous Thromboembolism; Young Adult | 2011 |
Oral contraceptives and venous thromboembolism: pill scares and public health.
Topics: Aged; Androstenes; Case-Control Studies; Contraceptives, Oral, Combined; Fear; Female; Humans; Levonorgestrel; Middle Aged; Prospective Studies; Public Health; Retrospective Studies; Risk Factors; Venous Thromboembolism | 2011 |
Risk of blood clots higher for oral contraceptives with certain progestins.
Topics: Androstenes; Contraceptives, Oral; Cyproterone; Denmark; Desogestrel; Ethinyl Estradiol; Female; Humans; Levonorgestrel; Norpregnenes; Progestins; Registries; Risk; Venous Thromboembolism | 2011 |
Debating the evidence: oral contraceptives containing drospirenone and risk of blood clots.
Topics: Androstenes; Contraceptives, Oral; Female; Humans; Risk Factors; Venous Thromboembolism | 2011 |
Combined oral contraceptives, venous thromboembolism, and the problem of interpreting large but incomplete datasets.
Topics: Adolescent; Adult; Age Factors; Androstenes; Body Mass Index; Contraceptives, Oral, Combined; Data Collection; Data Interpretation, Statistical; Desogestrel; Female; Humans; Middle Aged; Norpregnenes; Progesterone Congeners; Reproducibility of Results; Risk Factors; Venous Thromboembolism; Young Adult | 2012 |
ACOG Committee Opinion Number 540: Risk of venous thromboembolism among users of drospirenone-containing oral contraceptive pills.
Topics: Androstenes; Contraceptives, Oral; Female; Humans; Mineralocorticoid Receptor Antagonists; Pregnancy; Risk Factors; Venous Thromboembolism | 2012 |
Response to the letter from Dr. Szarewski.
Topics: Androstenes; Female; Humans; Mineralocorticoid Receptor Antagonists; Venous Thromboembolism | 2013 |
Another flawed database study.
Topics: Androstenes; Contraceptive Agents, Female; Desogestrel; Ethinyl Estradiol; Female; Humans; Mineralocorticoid Receptor Antagonists; Norgestrel; Venous Thromboembolism | 2013 |